Evaluation of the Preclinical Efficacy of Lurbinectedin in Malignant Pleural Mesothelioma

SIMPLE SUMMARY: The marine drug lurbinectedin revealed an unprecedented efficacy against patient-derived malignant pleural mesothelioma cells, regardless of the histological type and the BAP1 mutation status. By inducing strong DNA damages, it dramatically arrested cell cycle progression and induced...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancers (Basel)
Autors principals: Anobile, Dario P., Bironzo, Paolo, Picca, Francesca, Lingua, Marcello F., Morena, Deborah, Righi, Luisella, Napoli, Francesca, Papotti, Mauro G., Pittaro, Alessandra, Di Nicolantonio, Federica, Gigliotti, Chiara, Bussolino, Federico, Comunanza, Valentina, Guerrera, Francesco, Sandri, Alberto, Leo, Francesco, Libener, Roberta, Aviles, Pablo, Novello, Silvia, Taulli, Riccardo, Scagliotti, Giorgio V., Riganti, Chiara
Format: Artigo
Idioma:Inglês
Publicat: MDPI 2021
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8151304/
https://ncbi.nlm.nih.gov/pubmed/34066159
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13102332
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars